FDA Approves ETICOVO™ (etanercept-ykro), Samsung Bioepis' Second Anti-TNF Medicine in the United States - Yahoo Finance

FDA Approves ETICOVO™ (etanercept-ykro), Samsung Bioepis' Second Anti-TNF Medicine in the United States  Yahoo Finance

Samsung Bioepis expands autoimmune portfolio in the United States with FDA approval of ETICOVO™ , a biosimilar referencing ENBREL®i .



Comments

Popular posts from this blog

Fibromyalgia — Latest Stories — Pain News Network

Chronic Lyme arthritis: A mystery solved?

Epstein-Barr virus and autoimmune diseases